Marcel Müller
Novartis
17 Papers
301 Citations
Marcel Müller is an academic researcher from Novartis. The author has contributed to research in topics: Protein kinase C & Oligonucleotide. The author has an hindex of 12, co-authored 17 publications.
Chat about Author
Papers
Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C- raf kinase
TL;DR: It is suggested that antisense inhibitors targeted against C–raf–1 kinase may be of considerable value as antineoplastic agents that display activity against a wide spectrum of tumor types at well–tolerated doses.
511
A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and In vitro anti‐proliferative as well as In vivo anti‐tumor activity
Thomas Meyer,Urs Regenass,Doriano Fabbro,E. Alteri,J. Rösel,Marcel Müller,Giorgio Caravatti,Alex Matter +7 more
TL;DR: An association between PKC inhibition and anti‐proliferative and anti-tumor activity is suggested and staurosporine and CGP 41 251 exerted growth inhibition in the human bladder carcinoma line T‐24, human promyelocytic leukemia line HL‐60 and bovine corneal endothelial cells at concentrations which correlated well with in vitroPKC inhibition.
459
•Journal Article
Second Generation of Antisense Oligonucleotides: From Nuclease Resistance to Biological Efficacy in Animals.
Karl-Heinz Altmann,Nicholas M. Dean,Doriano Fabbro,S. M. Freier,Thomas Geiger,Robert Häner,D. Husken,Pierre Martin,Brett P. Monia,Marcel Müller,F. Natt,P. Nicklin,J. Phillips,Uwe Pieles,H. Sasmor,H. E. Moser +15 more
TL;DR: Chimeric oligonucleotides with 2'-O-methoxyethyl ribonucleosides, 8b, in the wings and a central DNA-phosphorothioate window were shown to efficiently downregulate C-'raf' kinase and PKC-α messenger-RNA in tumor cell lines resulting in a profound inhibition of cell proliferation.
246
Second-generation antisense oligonucleotides : structure-activity relationships and the design of improved signal-transduction inhibitors
Karl-Heinz Altmann,Doriano Fabbro,Nicholas M. Dean,Thomas Geiger,Brett P. Monia,Marcel Müller,P. Nicklin +6 more
TL;DR: The structure-activity relationships and the design of improved signal-transduction inhibitors in second-generation antisense oligonucleotides are described, paving the way for the development of new drugs to treat cancer.
181
Anti-tumor effects of tumor necrosis factor in combination with chemotherapeutic agents.
TL;DR: Histological analysis revealed a potentiation of the TNF‐induced necrosis by cyclophosphamide and increased hyperemia and extravasation of erythrocytes could be found in tumors of animals treated with the drug combination.
81